Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Biopsy 9Specimen Handling 8Magnetic Resonance Spectroscopy 6duvelisib 5Cyclophosphamide 5ruxolitinib 4Vincristine 410-propargyl-10-deazaaminopterin 4pembrolizumab 3X-Rays 3Prednisone 3Etoposide 3Doxorubicin 3tazemetostat 2sodium-iodide symporter 2cemiplimab 2belinostat 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Disulfides 2Cytarabine 2Bortezomib 2Azacitidine 2venetoclax 1talimogene laherparepvec 1romidepsin 1prednylidene 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × EPOCH protocol × 90 days × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡